2026-10-29T23:05:46Zhttps://munzur-rdlopen.rawdatalibrary.net/oai/request

oai:munzur-rdlopen.rawdatalibrary.net:munzur/20322026-10-28T15:29:21Zopenairecom_munzur_1col_munzur_2com_munzur_8col_munzur_159

Virtual reality for COPD exacerbation: A randomized controlled trialKizmaz, ErhanTelli Atalay, OrçinÇetin, NazlıUğurlu, ErhanCOPDExacerbationPulmonary rehabilitationVirtual realityBackground: Pulmonary rehabilitation (PR) is an effective treatment method for chronic obstructive pulmonary disease (COPD). However, individuals with chronic diseases that require lifelong treatment and experience exacerbations need motivational methods. Objectives: The aim of this study was to examine the effects of virtual reality on symptoms, daily living activity, functional capacity, anxiety and depression levels in COPD exacerbation. Methods: Fifty patients hospitalized for COPD exacerbation were included in the study. They were randomly assigned to two groups. Twenty-five patients participated in a traditional PR (once-daily until discharge), including pedaling exercises. The second/25 patients followed the same protocol but experienced cycling simulation in the forest via virtual reality (VR + PR). All patients were evaluated using 1-minute/Sit-to-Stand test (STST), modified-Medical Research Council (mMRC) scale, COPD Assessment test (CAT), Hospital Anxiety and Depression Scale (HADS), and London Chest Activities of Daily Living (LCADL) before and after the treatment. Results: The STST showed an increase in both groups post-treatment, notably higher in the VR + PR (p = 0.037). Dyspnea levels and CAT scores decreased in all patients, but the decrease was greater in the PR + VR group for both parameters (p = 0.062, p = 0.003; respectively). Both groups experienced a reduction in the HADS scores compared to the pre-treatment, with a more significant decrease in depression and the total score in the VR + PR (p < 0.05). LCADL's sub-parameters and total score, excluding household, decreased in both groups after treatment (p < 0.05). The improvement was more substantial in the VR + PR. Conclusions: Virtual reality provides benefits in the management of COPD exacerbations and can be used safely. Clinical trial registiration: Registered at clinicaltrials.gov, registration ID: NCT05687396, URL: www.clinicaltrials.gov.W.B. Saunders Ltd2024Articlehttps://rdlopen.rawdatalibrary.net/r/munzur/2032https://doi.org/10.1016/j.rmed.2024.1076960954-6111enRespiratory Medicineinfo:eu-repo/semantics/closedAccessinfo:eu-repo/semantics/articlehttps://munzur-rdlopen.rawdatalibrary.net/tr/items/munzur/2032